HAAH mAb exhibited high level binding to the four tumor cell lines (breast carcinoma MCF-7, hepatic carcinoma SMMC-7721, cervix cancer Hela and ovary cancer SKOV) and lower degrees of binding were observed with the other three (renal adenocarcinoma ACHN, bladder cancer BIU-87 and laryngeal cancer Hep-2).